Engineering an Antibiotic to Fight Cancer: Optimization of the Novobiocin Scaffold to Produce Anti-Proliferative Agents by Zhao, Huiping et al.
Engineering an Antibiotic to Fight Cancer: Optimization of the
Novobiocin Scaffold to Produce Anti-Proliferative Agents
Huiping Zhao†,1, Alison C. Donnelly†,1, Bhaskar R. Kusuma†,1, Gary E. L. Brandt†, Douglas
Brown§, Roger A. Rajewski^, George Vielhauer‡, Jeffrey Holzbeierlein‡, Mark S. Cohen‡,
and Brian S. J. Blagg†,*
†Department of Medicinal Chemistry, 1251 Wescoe Hall Drive, Malott 4070, The University of
Kansas, Lawrence, Kansas 66045-7563
§Biotechnology Innovation & Optimization Center, 2099 Constant Avenue, The University of
Kansas, Lawrence, KS 66047-2535
^Department of Pharmaceutical Chemistry, 2095 Constant Avenue, The University of Kansas,
Lawrence, Kansas 66047-2535
‡Department of Urology, The University of Kansas Medical Center, 3901 Rainbow Blvd., Mail
Stop 3016, Kansas City, Kansas 66160
Abstract
Development of the DNA gyrase inhibitor, novobiocin, into a selective Hsp90 inhibitor was
accomplished through structural modifications to the amide side chain, coumarin ring, and sugar
moiety. These species exhibit ~700-fold improved anti-proliferative activity versus the natural
product as evaluated by cellular efficacies against breast, colon, prostate, lung, and other cancer
cell lines. Utilization of structure–activity relationships established for three novobiocin synthons
produced optimized scaffolds, which manifest mid-nanomolar activity against a panel of cancer
cell lines and serve as lead compounds that manifest their activities through Hsp90 inhibition.
Introduction
The Hsp90 molecular chaperone has emerged as a promising target for the treatment of
cancer.1 While most current therapies are directed at disrupting a single molecular function,
Hsp90 is distinctive as it serves to modulate multiple oncogenic pathways. Moreover, Hsp90
is overexpressed in human malignancies and its inhibition provides a unique opportunity to
develop small molecules that exhibit high differential selectivity.1–4 There are more than
150 client proteins dependent upon Hsp90 for their folding and conformational maintenance,
many of which contribute to cancer cell proliferation and growth.5–12 Small molecule Hsp90
inhibitors transform the normal protein folding machinery into a catalyst for protein
degradation via utilization of the ubiquitin-proteasome pathway.13, 14 As such, Hsp90
inhibition is similar to a combinatorial attack, in which multiple signaling pathways that
contribute to malignancy are simultaneously disrupted.1, 2, 15–17
Novobiocin (Figure 1), a member of the coumermycin family of antibiotics, manifests
potent antimicrobial activity through inhibition of DNA gyrase-mediated ATP-
hydrolysis.18–22 Co-crystal structures of DNA gyrase B bound to novobiocin and ADP
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revealed both molecules to bind in an atypical, bent conformation.23–25 It was this unique
binding conformation that led Neckers and coworkers to hypothesize that novobiocin
exhibits its anti-tumor activity (~700 µM) against SKBr3 breast cancer cells through Hsp90
inhibition. Through subsequent Western blot analyses, Neckers and coworkers confirmed
that novobiocin induces degradation of Hsp90-dependent clients in a concentration-
dependent manner, a hallmark of Hsp90 inhibition. In contrast to other Hsp90 inhibitors, it
was shown that novobiocin bound to the C-terminus, revealing a previously unrecognized
binding site, and perhaps, a new opportunity to modulate the Hsp90 protein folding
machinery.26
Although no co-crystal structure of Hsp90 bound to C-terminal inhibitors has been reported,
the structure and function of the Hsp90 C-terminal nucleotide binding site are under intense
investigation. Compounds exhibiting higher affinity for Hsp90 than novobiocin are likely to
provide the tools necessary for elucidation of the Hsp90 C-terminal nucleotide-binding
pocket and provide new Hsp90 modulators that manifest chemotherapeutic potential.27 The
poor Hsp90 inhibitory activity of novobiocin26 has been greatly improved upon by the
preparation of analogues. Yu and co-workers produced a library of compounds that
established the first structure–activity relationships for novobiocin as an Hsp90 inhibitor.
This focused library explored essential features of the benzamide side chain, coumarin core
and noviose sugar, highlighting that attachment of noviose to the 7-position and an amide
linker at the 3-position of the coumarin ring are critical for Hsp90 inhibitory activity.
Moreover, modifications to the sugar identified the diol as most potent, versus the cyclic
carbonate and corresponding carbamates as found in novobiocin.28
Compound 1 (Figure 2) was the most notable compound identified from this library. 1, with
a shortened N-acyl side chain, a 4-deshydroxy substituent and no carbamoyl group on
noviose, induced degradation of Hsp90-dependent client proteins at ~70-fold lower
concentration than novobiocin.28 However, in contrast to N-terminal inhibitors, 1 induced
Hsp90 at concentrations 1000–10000-fold lower than that required for client protein
degradation, a phenomenon that had not been previously observed. Due to its activity and
non-toxic nature, 1 was evaluated as a neuroprotective agent and produced an EC50 of 6 nM
in a culture model for Alzheimer’s disease.28
To confirm SAR trends observed by Yu and co-workers, two natural product analogues, 2
and 3 (Figure 2), were designed and subsequently evaluated by Burlison and co-workers.
This study aimed at elucidating functionalities on novobiocin that are responsible for DNA
gyrase inhibition and to deconvolute Hsp90-selective inhibitory compounds. Studies with
these compounds confirmed that the 4-hydroxyl and the 3’-carbamate are detrimental to
Hsp90 inhibitory activity, but critical for DNA gyrase inhibition.29 This study confirmed the
trends observed from the 1 library and produced the first selective inhibitors of the Hsp90 C-
terminus.
Based on the cytotoxicity of coumermycin A1 (Figure 3), another member of the
coumermycin family of antibiotics, it appeared that dimerization could increase Hsp90
inhibitory activity. Burlison and co-workers dimerized 1 in an attempt to transform a non-
toxic agent into a more potent analogue. The resulting compound, 5, the most potent
identified, exhibited low micromolar anti-proliferative activity, but did not induce the heat
shock response. These results suggested that modification of the amide side chain could
convert a non-toxic molecule into an anti-proliferative agent.31 Consequently, a series of
monomeric species based on 1 was synthesized and evaluated in cell proliferation studies.32
Monomeric analogues were designed to include biaryl and heterocyclic amide derivatives
that explored hydrogen-bonding interactions with the putative binding pocket that typically
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accommodates the prenylated benzamide of novobiocin. This library identified key
functionalities and established the first set of SAR for the amide side chain (Figure 4).
The coumarin core of novobiocin was recently explored and SAR established. Derivatives of
1 with variations to the coumarin ring were designed to probe the importance of interactions
manifested by the natural substrate purine ring as well the size and nature of the novobiocin
binding pocket. The 6- and 8-positions of the coumarin scaffold proved tolerable to
substitution, and incorporation of alkoxy groups at these locations led to improved inhibitory
activity. Moreover, the lactone moiety of the coumarin ring was found to be dispensable
(Figure 5).33
Renoir and co-workers examined the role of noviose in Hsp90 inhibition. Their structure–
activity relationship studies demonstrated that Hsp90 inhibition was observed by analogues
that lack the noviose moiety, if a tosyl substituent is attached to the C-4 or C-7 position of
the coumarin. These analogues manifested mid-micromolar IC50 values.34 In a subsequent
paper, the same group suggested that Hsp90 inhibition can be enhanced by removal of C7/
C8 substituents in denoviose analogues bearing a tosyl group at the 4-position. These studies
produced inhibitors with simplified coumarins that also exhibited mid-micromolar IC50
values.35 The compounds produced in these two publications represented the first
novobiocin analogues that lacked the noviose sugar while manifesting Hsp90 inhibition.
The noviose sugar found in novobiocin is complex and is prepared via laborious efforts.
Even the most efficient syntheses of noviose require more than 10 steps and the overall
yields are less than optimal.36 In an effort to gain further insight into this region of
novobiocin, simplified noviose derivatives were attached to the novobiocin core. This study,
which resulted in compounds that exhibit a 700-fold improvement in activity over
novobiocin, indicated that while the sugar moiety plays a critical role in maintaining binding
interactions with Hsp90, not all functionalities are necessary.
Sugar mimics were originally attached to the 7-position of coumarin containing an 8-methyl
substituent and a biaryl benzamide. The most potent coumarin scaffolds obtained from the
coumarin studies were coupled with the optimal biaryl side chain to yield a scaffold upon
which sugar surrogates were appended.32, 33 Based on the inhibitory activity manifested by
the biaryl analogues, the most promising sugar surrogates were coupled with coumarins
containing the 2-indole side chain.32 The simplified sugars and related azasugars were found
to conserve structural units present in noviose, but lacked the complexity of multi-step
synthesis. These sugar surrogates were designed to probe potential hydrogen bonds as well
as to determine the dimensions of the pocket. In addition to simplified sugars, several
surrogates containing heteroatoms and various appendages were also explored. These
diverse sugar and non-sugar analogues simplify the preparation of novobiocin analogues,
while providing a handle to improve both solubility and efficacy. The design, synthesis and
biological evaluation of these optimized compounds are reported herein.
Results and Discussion
Design, synthesis and evaluation of modified sugar analogues of novobiocin
Numerous biologically active natural products contain carbohydrates appended to their
scaffolds that serve to increase solubility and provide interactions with their cognate
receptor. In many cases, removal of the carbohydrate moiety renders the aglycon inactive,
whereas alteration of the sugar ring size can alter affinity of the compounds toward specific
targets.37–39 Modifications to the noviose pyranose ring were proposed to elucidate
functionalities required for inhibitory activity, as well as to determine whether different
sized sugars can be utilized as replacements for noviose. Thus, 5-, 6- and 7-membered
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sugars were synthesized and coupled to the aforementioned scaffolds to determine optimal
interactions. When available, the α- and β-anomers were also evaluated. A set of protected
mono-, di- and trihydroxylated furanoses, pyranoses and oxepanose sugars previously
synthesized by Yu and coworkers40 (E–L, Figure 6) was chosen based on these
considerations.
The analogues were assembled in modular fashion, allowing sequential coupling of sugars
and the biaryl acid side chain with the desired scaffold. As shown in the retrosynthetic
analysis (Scheme 1), the biaryl acid side chain was assembled through a Suzuki coupling
reaction, as described previously.33 Next, the biaryl acid was converted to its corresponding
acid chloride and then coupled with the protected coumarin, 9. Finally, Mitsunobu
etherification between coumarin phenols 6a–c and sugars E–L yielded the desired analogues
in good yields.
Synthesis of these analogues, as described in Scheme 2, began via protection of phenol
732, 33 as the corresponding ester, 8. Next, hydrogenolysis was employed to liberate
vinylogous amide 9, which was subsequently coupled with biaryl acyl chloride, 11. The
biaryl acid chloride was generated from the corresponding biaryl acid 10, as described
previously.33 Finally, solvolysis of ester 12 afforded phenol 6a–c in good yield.
Coumarin phenols 6a–c and protected sugar F were coupled via a Mitsunobu etherification
to yield an inseparable mixture of diastereomers, 13, in a 3:2 ratio, respectively (Scheme 3).
The cyclic carbonates of the resulting mixture were solvolyzed to afford a mixture of diols
14 and 15, which were separated by silica chromatography. The stereochemistry at the
anomeric carbon was assigned by 2D-NOESY spectroscopy.
An anomeric mixture of compound 13 was synthesized via Mitsunobu etherification
between sugar F and coumarin 6. Likewise, the Mitsunobu conditions were used to append
sugar G to coumarin 6 and furnish the anomeric mixture of compound 16, and to attach
sugar H to coumarin 6 to yield anomeric mixture 19. Solvolysis of the cyclic carbonate
present in 13 furnished a mixture of separable diols, 13 and 14. Moreover, benzoyl (Bz)
deprotection of 16 yielded analogues 17 and 18 in a 3:2 ratio,5 while TIPS removal of 19
furnished analogues 20 and 21 in a 4:3 ratio. Not surprisingly, a single diastereomer of 22
was exclusively formed when coumarin 6 and protected sugar E were subjected to
Mitsunobu conditions. Subsequent deprotection of the acetonide and benzyl protecting
groups afforded triol 23 in good yield (Scheme 3).
As shown in Scheme 4, protected furanose sugars J–L were coupled with coumarin 6
enlisting Mitsunobu etherification to afford the corresponding analogues in good yields.
Mitsunobu coupling of protected sugar J with coumarin 6 yielded exclusively diastereomer
24, which was subsequently hydrolyzed to afford diol 25. Mitsunobu etherification was used
to append sugar K to yield analogue 26, which, after silyl removal, furnished separable
compounds 27 and 28. Likewise, the same conditions were applied to append sugar L to 29,
which, after silyl cleavage, yielded analogues 30 and 31. Protected oxepanose I was coupled
to coumarin 6 using Mitsunobu conditions to afford 32 as the major product, which was
hydrolyzed to give 33.
In addition to the variable-sized sugar-containing analogues, cyclohexyl analogues were
designed to examine if a sugar was necessary. Additionally, to probe the tolerance of steric
bulk, analogues with and without alkyl substituents were pursued. Many of the simplified
cyclohexyl sugar mimics were accessible using common procedures (Scheme 5), such as
reduction with lithium aluminum hydride to produce compounds 37 and 38, or Luche
reduction to yield 39. Compounds containing a double bond were designed to be coupled
with the scaffold and subsequently oxidized to the corresponding diols (e.g., 43–45).
Zhao et al. Page 4













Upon construction of the modified sugar analogues of novobiocin, the compounds were
evaluated for anti-proliferative activity against SKBr3 (estrogen receptor negative, HER2
over-expressing breast cancer cells), MCF-7 (estrogen receptor positive breast cancer cells),
LNCaP-LN3 (androgen-dependent human prostate cancer cells) and PC3-MM2 (androgen-
independent prostate cancer cells) cell lines. As shown in Table 1, analogues containing six-
membered pyranose moieties (scaffold A) were found to be the most active compounds
against the two breast cancer cell lines. Analogues containing dihydroxyl groups
consistently exhibited good to modest anti-proliferative activities against both breast cancer
cell lines. In contrast, analogues that contained a single hydroxyl at the 2’-position proved
inactive, while most analogues with a 3’-hydroxyl exhibited modest activity. These data
indicate that the 3’-position hydroxy group is essential for anti-proliferative activity.
Interestingly, the natural substrate for the C-terminal pocket of Hsp90, ATP/ADP, also
contains a 3’-hydroxyl. Although the β epimer exhibited better activity than its α counterpart
(14a–c vs. 15a–c) for most analogues, this was not a general trend observed throughout the
series (120a–c vs. 21a–c). In addition, the majority of the compounds from this series
demonstrated modest activity against the prostate cancer cell lines. Notably, however, some
compounds (18a) that were completely inactive against both breast cancer cells lines were
efficacious against prostate cancer.
Analogues containing a cyclohexyl moiety in lieu of the sugar demonstrated a range of
activities. While analogues containing an 8-methyl group (43a, 44a, 45a) were inactive
against breast cancer, those with an 8-methoxy group (43b, 44b, 45b) exhibited an IC50
value of ~10 µM, which is comparable to its noviosylated counterpart.33 Interestingly, the
gem-dimethyl group is well tolerated in the case of the 8-methoxy coumarin (43b), but
detrimental in the case of the 6-methoxy coumarin (43c). This finding suggests a mutually
exclusive orientation between the gem-dimethyl group and substituents on the coumarin,
which may preclude proper binding orientation.
Overall, this library containing sugar surrogates and cyclohexyl groups confirmed the 3’-
hydroxy as the most important functional group. Moreover, the 4’-methoxy, 5’-gem-
dimethyl and anomeric oxygen found in noviose were identified as dispensable moieties.
Several analogues (15b, 24c and 37a) exhibited low micromolar anti-proliferative activity
against SKBr3 cells, which makes them ~500-fold more active than novobiocin.
Design, synthesis and biological evaluation of azasugar analogues of novobiocin
After evaluation of the initial library, it was proposed that other six-membered heteroatom-
containing ring systems may serve as replacements for noviose. N-heterocycles are found in
a wide variety of biologically active compounds, imparting solubility to otherwise insoluble
aglycons. Several heterocycles were designed to probe hydrogen-bonding interactions with
the binding pocket as well as to improve solubility.
In modular fashion, the analogues were assembled similarly to those described previously,
in modular fashion, allowing sequential coupling of various sugar surrogates and the biaryl
side chain. As shown in the retrosynthetic analysis depicted in Scheme 6, the biaryl acid
chloride, prepared from the corresponding biaryl acid, was coupled with coumarin 12.
Following deprotection, coumarin phenol 6 was etherified using Mitsunobu conditions, to
yield the desired analogues.
In order to avoid synthetic complications, only a single hydroxyl group was installed on the
piperidine ring prior to Mitsunobu coupling and the amine was masked as the carbamate, 46.
With compound 6 and 46 in hand, compound 47 was synthesized via Mitsunobu
etherification, followed by deprotection to yield amine 48 in quantitative yield. Acetylation
of 48 gave amide 50, while treatment with methyl iodide furnished the tertiary amine, 51,
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which underwent dihydroxylation with OsO4/NMO to give 55. Dihydroxylation of 47
afforded compound 49, which, upon removal of Boc, afforded 52. Compounds 53 and 54
were synthesized from compound 50 via reduction or dihydroxylation conditions,
respectively (Scheme 7).
In addition, compounds lacking the diol functionality and containing a transposed nitrogen
within the heterocycle were selected for investigation. Boc-protected 1,3- or 1,4-azasugars
were coupled with phenol 6 to afford compounds 56 and 58, which were subsequently
deprotected to yield amines 57 and 59. Similarly, N-methylated analogues 60 and 61 were
synthesized via Mitsunobu etherification with commercially available piperidines in good
yields (Scheme 8).
Upon construction of the azasugar-containing analogues, they were evaluated for anti-
proliferative activity against two breast and two prostate cancer cell lines. As shown in
Table 3, the activity against breast cancer cells exhibited by the majority of these secondary
and tertiary amines varied between 1–3 µM, making them ~700-fold more active than
novobiocin. Although dihydroxylation of the piperidine ring is well-tolerated when
appended to the 8-methyl scaffold (52a), this is not the case for the other two scaffolds (52b
and 52c). These data suggest that dihydroxylation of the piperidine ring is not essential for
anti-proliferative activity. Inclusion of unsaturation within the piperidine ring is also well
tolerated (scaffold A vs. C and D, Table 3) while methylation of the amine within this
unsaturated ring decreases activity (48 vs. 51). It was observed that acetylation of the amine
functionality (50a, 53a, 54a) severely decreased solubility, and produced inactive
compounds. Although insolubility can be overcome through dihydroxylation of the
piperidine ring (54a), the resulting compound is ~5-fold less active than secondary or
tertiary amines. There is no significant effect when the nitrogen is transposed within the
piperidine ring, as all of the analogues exhibited activity between ~1–3 µM. In addition,
secondary amines exhibited comparable activity to methylated tertiary amines (57 vs. 60, 59
vs. 61). Overall, these azasugar analogues consistently exhibited low micromolar anti-
proliferative activity, representing an improved sugar mimic.
Design, synthesis and biological evaluation of novobiocin analogues with acyclic sugar
replacements
The promising results obtained when azasugars were appended to these scaffolds
encouraged the synthesis of acyclic nitrogen-containing replacements. To probe the
importance of a constrained ring system, a library of ring-opened, amine-containing sugar
surrogates was designed. A series of heteroatom-containing aliphatic chains were
synthesized to impart flexibility and explore the potential of additional interactions with the
binding pocket. Aliphatic amines, either commercially available or prepared over a modest
number of steps, were appended to coumarin core 6 through standard Mitsunobu coupling to
yield compounds 64–66. The dihydroxylated aliphatic chain was attached via treatment with
allyl bromide followed by dihydroxylation to afford compound 68 (Scheme 9).
In addition to the aliphatic amine analogues synthesized, several simplified non-sugar
molecules were appended in lieu of the noviose sugar. These non-sugars represent simplified
functionalities manifested by compound 4,30 a recently described inhibitor of the Hsp90 C-
terminus (Figure 2).30 Substitutions were selected to probe hydrogen-bonding interactions,
dimensions, and improve solubility. Carbamates (69–71) with variable substitution prepared
through standard conditions. Phosphate ester 71 was introduced through an esterification
reaction to increase the hydrophilicity of the inhibitor and finally, methyl and toluene
sulfonic esters (73, 74) were incorporated using the corresponding sulfonic chlorides to
explore both the hydrogen bonding network and dimensions of the pocket similarly to that
reported by Renoir and co-workers34 (Scheme 10).
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Upon construction of these alkyl and non-sugar compounds, they were evaluated for anti-
proliferative activity against various cancer cell lines. The anti-proliferative data are
summarized in Tables 4 and 5. All of the tertiary amine analogues demonstrated notable
anti-proliferative activity of ~1 µM, while the secondary amine analogues maintained
activity of ~3–5 µM against both breast cancer cell lines. The tertiary amine analogues
homologated by two methylene groups (65a–c) exhibited activity of 1–3 µM, which is
comparable to the piperidine analogues. Moreover, homologation by three methylene groups
(66a–c) resulted in compounds that manifested anti-proliferative activity in the mid-
nanomolar range, a finding that is consistent with the piperidine ring analogues. In contrast,
the diol-containing analogues, when appended to the 8-methyl (68a) or 8-methoxy (68b)
coumarin scaffolds were inactive, but resulted in modest activity when appended to the 6-
methoxy coumarin (68c). Furthermore, the aliphatic amine and corresponding
dihydroxylated analogues manifested modest activities against the prostate cancer cell lines
as well.
The anti-proliferative data for the non-sugar analogues revealed several interesting trends.
The free phenol of each scaffold was nearly equal in activity to its noviosylated counterpart.
Moreover, the acetylated phenols, in the case of the 8-methyl and 6-methoxy coumarins,
displayed activities of ~1 µM against breast cancer cells. Similarly, the carbamate and
methylated carbamate were well tolerated when appended to 8-methyl and 6-methoxy
coumarins, resulting in low micromolar analogues. Addition of another methyl group to the
carbamate severely compromised activity. The methyl sulfonic ester was only tolerated
when appended to the 8-methyl scaffold, while the toluene sulfonic ester was not tolerated
by any analogue. Likewise, addition of the phosphate ester decreased activity of the
analogues. Overall, hydrogen bonding and limited hydrophobic bulk are essential features
for optimal binding.
Synthesis of optimized scaffolds using most promising noviose replacements
Based on the biological evaluation discussed thus far, we identified the N-methyl-4-
hydroxy-piperidine and 3-(dimethylamino)propan-1-ol as optimal noviose replacements.
Therefore, these surrogates were appended to three previously identified and optimized
coumarin scaffolds, containing either the 2-indole or prenylated benzamide side chain in lieu
of the biaryl system.32, 42 As detailed earlier, the analogues were assembled in a modular
fashion, allowing sequential coupling of sugar mimics and the indole acid chloride or
benzoic acid chloride with the desired scaffold (Scheme 11). Unlike previously discussed
scaffolds, the Mitsunobu ether coupling was performed prior to amide coupling due to
solubility issues arising from the indole-containing free phenol.
As seen in Scheme 12, phenol 732, 33 was coupled with the azasugar using Mitsunobu
conditions to yield protected scaffold 75. The vinylogous amide was liberated via
hydrogenolysis and coupled with indole acyl chloride 76, which was generated from
commercially available indole acid, to yield 78.32 The analogues containing a prenylated
benzamide side chain (77) were assembled via the same sequence (Scheme 12), to yield
alkyl amine analogues 79 and 80. The prenylated side chain, 77, was assembled as described
previously by Burlison and co-workers.29
These compounds were evaluated for their anti-proliferative activity. The piperidine-
containing analogues with an indole side chain (78a–c) exhibited increased anti-proliferative
activity when attached to the 8-methyl and 6-methoxy coumarin (78a and 78c). 78c was
notably 10-fold more active against SKBr3 cells when compared to its biaryl counterpart
61c. In contrast, attachment of this sugar surrogate to the 8-methoxy coumarin (78b)
compromised its activity versus the biaryl-containing analogue 61b. In the case of the
prenylated benzamide side chain (79a–c and 80a–c), attachment of the azasugar increased
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activity against both cell lines, with the 6-methoxy coumarin manifesting superior activity
(79c and 80c). In addition, the intermediate acetylated phenols 79a–c demonstrated
comparable activity to the hydrolyzed phenol products 80a–c. Based on the results obtained
with the biaryl containing analogues, it was proposed that appendage of the aliphatic amine
to the coumarins with an indole side chain would result in increased activity (see Table 4).
However, the anti-proliferative activity of these indole analogues (82a–c) was maintained or
slightly decreased in nearly every case. When these alkyl sugars were attached to the
coumarins containing a prenylated benzamide side chain, the compounds manifested anti-
proliferative activity in the mid-nanomolar range against SKBr3 cells. Moreover,
compounds built upon the 6-methoxy coumarin scaffold (83c and 84c) exhibited the best
activity against both cell lines.
Finally, several analogues from each of the libraries were selected for testing against a panel
of melanoma and head and neck squamous cell carcinoma cell lines. In preliminary studies,
C-terminal Hsp90 inhibitors have demonstrated modest activity against melanoma cells and
have shown promise in treating head and neck cancers as well. Unpublished in vivo data
produced by the Cohen lab has demonstrated tumor regression upon sustained treatment
with a C-terminal Hsp90 inhibitor previously synthesized.33 Analogues were selected that
exhibited diverse structural features to probe the efficacy of these analogues against these
cancers. B16F10 (murine melanoma), SKMEL28 (human melanoma), MDA1986 (human
head and neck squamous cell carcinoma (HNSCC)), and JMAR (human oral squamous cell
carcinoma) were selected for this panel of testing. The majority of the analogues tested
manifested mid to low micromolar activity against these cell lines. While some of the
compounds exhibited better activity against melanoma than head and neck cancers (61b),
others were potent in a specific melanoma (57b) or a specific head and neck (17a) cell line.
The low micromolar activity of 78c and 82c against all of the cell lines warrant further
investigation.
Validation of Hsp90 inhibition via Western blot analysis
To confirm that the anti-proliferative activities exhibited by the optimized sugar analogues
result from Hsp90 inhibition, analogues 80c and 83c were evaluated by Western blot
analyses (Figure 7). Notably, compounds 61a, 12b, 70a, and 87 have already been shown to
exert their anti-proliferative activities through an Hsp90-dependent mechanism, as
confirmed through previously executed Western blot analyses.30, 33, 41 It was essential that
these optimized derivatives demonstrate selective Hsp90-dependent client protein
degradation, versus a loading control, to confirm the compounds reported herein also
manifest Hsp90 inhibition. Figure 7 shows that in MCF-7 cells, the Hsp90-dependent client
proteins Akt, Raf-1, and Her2 were degraded in a concentration-dependent manner upon
treatment with the compounds. Hsp90 client protein degradation occurred at concentrations
that paralleled the observed anti-proliferative IC50 values of 0.54 ± 0.03 µM, for 80c and
0.70 ± 0.04 µM for 83c confirming that Hsp90-dependent client protein degradation is
causative for inhibition of cell growth. Furthermore, Hsp90 protein levels remained constant
at all concentrations tested, which is consistent with C-terminal Hsp90 inhibition. Since the
non-Hsp90-dependent protein, actin, was not affected by these analogues, it was concluded
that selective degradation of Hsp90-dependent proteins occurred.
Conclusion
Several libraries of novobiocin analogues with various structural features were designed,
synthesized and evaluated. From the library of sugar mimics, we identified the pyranose as
optimal and that a 2’-hydroxy group is indispensable. Several low micromolar analogues
containing modified sugars were also identified. From the series of azasugar-containing
analogues, we concluded that replacement of noviose with a piperidine ring resulted in
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consistent low micromolar anti-proliferative activities. The piperidine sugars confirmed that
interactions made between noviose and the binding pocket could also be maintained with
azasugars. In addition, the acyclic library produced several aliphatic sugar surrogates that
manifested mid-nanomolar activity. This library confirmed that flexibility is tolerated and
that noviose can be replaced with a simple acyclic moiety to maximize the potency of
novobiocin analogues. Finally, the synthesis of optimized scaffolds with various cytotoxic
benzamide side chains identified several novobiocin analogues that exhibited low nanomolar
anti-proliferative activity. These analogues confirmed that results obtained from earlier
studies could be applied to these appendages and produce compounds that warrant further
study.
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Structures of 1, 2, 3, and 4.28–30
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Structures of 5 and coumermycin A1.
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5-, 6-, and 7-membered noviose alternatives.
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Western blot analyses of Hsp90 client protein degradation assays against MCF-7 cells.
Concentrations (in µM) of 80c (top) and 83c (bottom) are indicated above each lane. G
(geldanamycin, 500 nM) and D (DMSO) were respectively employed as positive and
negative controls.
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Retrosynthesis of novobiocin biaryl analogues with sugars E–L.
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Synthesis of phenol 6.
Zhao et al. Page 20














Synthesis of pyranose-containing biaryl analogues.
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Synthesis of furanose- and oxepanose-containing biaryl analogues.
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Synthesis of cyclohexyl-containing biaryl analogues.
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Retrosynthesis of azasugar-containing biaryl analogues.
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Synthesis of 1,3-azasugar-containing biaryl analogues.
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Synthesis of 1,4-azasugar biaryl analogues.
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Synthesis of alkyl sugar biaryl analogues.
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Synthesis of non-sugar biaryl analogues.
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Retrosynthesis of azasugar indole novobiocin analogues.
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Synthesis of compound optimized compounds.
Zhao et al. Page 30






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Zhao et al. Page 41
Table 7
Anti-proliferative activity of selected analogues against melanoma and HNSCC.
Compound
(IC50, µM)
B16F10 SKMEL28 MDA1986 JMAR
6b 5.77 ± 0.96a 12.40 ± 0.64a 6.70 ± 1.20a 24.60 ± 1.92a
12a 2.30 ± 0.32 2.14 ± 0.08 1.67 ± 0.16 12.60 ± 0.40
14a 37.50 ± 6.56 14.90 ± 2.88 13.40 ± 4.24 2.79 ± 0.64
15a 8.56 ± 2.16 15.80 ± 0.48 3.70 ± 0.64 6.14 ± 1.28
17a 1.01 ± 0.48 1.47 ± 0.24 0.81 ± 0.40 16.10 ± 2.16
18a 10.40 ± 1.20 19.60 ± 2.48 18.80 ± 3.68 3.60 ± 0.40
23a 9.60 ± 1.12 10.65 ± 0.40 5.70 ± 0.56 5.80 ± 1.04
25a 4.55 ± 1.20 5.74 ± 2.08 1.94 ± 0.40 12.64 ± 1.28
25b 1.30 ± 0.16 6.41 ± 0.56 5.73 ± 0.96 2.71 ± 0.32
27a 42.70 ± 3.36 18.40 ± 2.96 21.40 ± 3.12 14.90 ± 3.68
30a 12.70 ± 1.44 21.40 ± 3.28 6.90 ± 2.08 24.10 ± 3.28
31a 9.37 ± 1.04 12.40 ± 2.48 18.80 ± 3.76 6.19 ± 2.48
33a >50 18.50 ± 5.76 22.90 ± 4.96 7.40 ± 1.68
40a >50 23.80 ± 2.88 24.40 ± 2.00 6.70 ± 2.32
41a >50 20.60 ± 2.16 21.80 ± 4.32 24.90 ± 2.80
42a >50 18.60 ± 2.00 22.40 ± 3.36 7.50 ± 1.84
43a 15.90 ± 2.16 3.47 ± 1.20 18.80 ± 0.64 8.50 ± 1.68
44a 2.50 ± 0.48 11.41 ± 1.28 6.74 ± 2.08 2.73 ± 0.32
45a 14.10 ± 2.08 2.94 ± 1.20 17.90 ± 1.44 13.90 ± 2.00
48a 2.94 ± 0.08 5.41 ± 0.08 6.54 ± 0.56 3.40 ± 0.16
48b 3.41 ± 0.32 5.49 ± 1.12 5.97 ± 0.40 6.71 ± 0.24
48c 2.86 ± 0.24 5.41 ± 0.16 5.90 ± 0.40 11.60 ± 0.32
50c 21.40 ± 1.28 27.60 ± 1.20 25.10 ± 2.08 35.10 ± 1.20
51a 6.40 ± 1.92 10.79 ± 0.64 7.70 ± 0.56 11.40 ± 1.20
51b 6.47 ± 2.80 1.48 ± 0.48 2.36 ± 0.08 1.94 ± 0.16
51c 6.14 ± 0.64 31.50 ± 1.84 16.40 ± 1.68 18.40 ± 2.56
52a 2.80 ± 0.40 6.14 ± 1.28 5.60 ± 1.04 5.89 ± 0.48
52b 11.75 ± 0.40 11.40 ± 2.56 21.70 ± 1.12 11.60 ± 1.92
52c 5.04 ± 0.32 13.80 ± 2.56 13.80 ± 3.44 11.50 ± 0.72
53a 12.40 ± 2.00 20.9 ± 2.56 22.40 ± 1.36 15.14 ± 1.84
53c 23.90 ± 2.88 29.40 ± 3.36 36.40 ± 1.20 32.80 ± 3.36
55b 6.58 ± 0.48 5.90 ± 1.68 5.90 ± 0.48 6.70 ± 0.24
55c 2.81 ± 0.32 5.73 ± 0.32 12.80 ± 1.28 24.50 ± 0.72
57a 1.90 ± 0.24 2.79 ± 0.96 23.60 ± 2.88 >50
57b 0.64 ± 0.08 14.67 ± 0.40 12.80 ± 1.92 12.70 ± 1.44
57c 1.84 ± 0.08 7.19 ± 0.24 6.40 ± 0.96 5.70 ± 0.32
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Compound
(IC50, µM)
B16F10 SKMEL28 MDA1986 JMAR
59a 2.76 ± 0.32 5.19 ± 0.16 2.74 ± 0.08 5.91 ± 0.40
59b 2.14 ± 0.08 16.45 ± 1.36 10.90 ± 0.64 12.60 ± 0.32
59c 1.84 ± 0.16 5.75 ± 0.24 14.60 ± 1.20 10.90 ± 0.48
60a 2.60 ± 0.32 6.14 ± 0.56 4.50 ± 0.08 12.60 ± 0.32
60b 1.51 ± 0.24 7.14 ± 0.40 11.40 ± 2.56 7.50 ± 0.64
60c 2.67 ± 0.32 5.86 ± 1.20 13.20 ± 0.72 19.10 ± 2.56
61b 0.41 ± 0.08 6.14 ± 0.32 13.10 ± 1.68 13.10 ± 0.64
61c 36.73 ± 0.64 3.74 ± 0.24 1.54 ± 0.08 1.84 ± 0.08
64a 37.40 ± 2.16 25.60 ± 2.96 21.90 ± 2.56 35.10 ± 2.16
65a 15.70 ± 4.56 14.70 ± 1.92 17.50 ± 3.28 18.40 ± 2.00
78c 1.19 ± 0.32 1.47 ± 0.08 1.42 ± 0.16 1.24 ± 0.24
82c 2.03 ± 0.08 1.35 ± 0.08 1.81 ± 0.32 2.65 ± 0.24
a
Values represent mean ± standard deviation for at least two separate experiments performed in triplicate.
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